Alpha Blue Ocean
VC Fund
Nassau, Bahamas
Alpha Blue Ocean is a dynamic family office that offers alternative financing solutions for listed companies through private investments or PIPEs. Alpha Blue Ocean spans all asset classes in order to provide structured investments & partnerships that are both flexible and pragmatic.ABO’s relationships are based on expertise and synergies,leveraging win-win situations and helping business partners reach their objectives and gain the recognition they deserve. Through meticulous due diligence and good practices, a special emphasis is placed on delivering sustainable solutions to both portfolio structures and investors.The team’s deep understanding of capital markets and ability to span across a wide range of asset classes provides maximum flexibility, and industry-leading and consistent risk-adjusted performances over time. Alpha Blue Ocean sees itself as a true partner to its portfolio companies and the management teams it invests in.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 75%
Last updated:
For AI agents: llms.txt
Industries Alpha Blue Ocean invests in
Stages Alpha Blue Ocean invests in
Countries Alpha Blue Ocean invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Post-IPO Debt
- $929k–$14M
Investment Focus
Industry
- Cannabis 3 (38%)
- Health Care 3 (38%)
- Biotechnology 3 (38%)
- Manufacturing 2 (25%)
- Medical Device 2 (25%)
Stage
- Post-IPO Debt 6 (75%)
- Series A 1 (13%)
- Post-IPO Equity 1 (13%)
Country
- Canada 2 (25%)
- France 2 (25%)
- Italy 1 (13%)
- United States 1 (13%)
- United Kingdom 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Amaury Mamou-Mani
Co-founder and Executive Director
|
Co-founder and Executive Director | Total investments: 0 | Find email | |
Amine Nedjai
CEO
|
CEO | Total investments: 8 | Find email | |
Hugo Pingray
Founder and co CIO
|
Founder and co CIO | Total investments: 0 | Find email | |
Olivia Blanchard
Chief Compliance Officer
|
Chief Compliance Officer | Total investments: 0 | Find email | |
Pierre Vannineuse
CIO & Founder
|
CIO & Founder | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Safe Orthopaedics
|
Safe Orthopaedics SA is a France-based company principally engaged in the medical devices industry. The Company focuses on the development and commercialization of products for use in spinal surgery. | $929.1K / Post-IPO Debt / Mar 11, 2024 | |
I.Ceram
|
I.Ceram SA is a company engaged in design and manufacture of joint implants. | $1.1M / Post-IPO Debt / Jan 16, 2024 | |
Netweek
|
Netweek is a book and periodical publishing company offering print periodicals, online newspapers, agency, and advertising services. Netweek aims to consolidate and improve its distinctive hyperlocalism features in order to become the go-to interlocutor for small and micro businesses. They provide communication means that are the latter'scommunication requirements which are currently comprised of editorial information products and special editions attached tools aimed at commercial segments deemed profitable for advertising revenues. Netweek serves as a point of contact for small and micro businesses. | $15.6M / Post-IPO Equity / Nov 23, 2022 | |
Tetra Bio-Pharma
|
Tetra Bio-Pharma is a biopharmaceutical company that focuses on cannabinoid-based drug discovery and development with a clinical program.Tetra Bio-Pharma specializes in combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio-pharma industryby regulators, physicians, and insurance companies. | $6M / Post-IPO Debt / Aug 11, 2022 | |
HAVN Life Sciences
|
HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support central nervous system health and enhance the capabilities of the mind. | $7M / Post-IPO Debt / Jul 21, 2022 | |
Cannaray
|
Cannaray is a leading European cannabis company stratifying medical THC and a CBD lifestyle brand.Cannaray CBD is the company’s flagship CBD wellness brand – founded to make CBD easy and accessible for millions of new people. Its product range includes CBD Oil Drops for day and night, Capsules, Gummies and Muscle Balm. All Cannaray CBD productsare formulated to be effective and enjoyable to use, triple-lab-tested for purity, and are packaged in the modern, bright, and optimistic Cannaray brand colours.Therismos is the company's medical division, which imports and distributes cannabis-based products for medical use (CBPM) across Europe. We strive to be the leading European full-service provider of medicinal cannabis through our innovative product solutions, valuable partnerships with strategic allies, and collaboration with world-class scientists and medical practitioners.We put patients at the heart of everything we do and aspire to improve their quality of life by offering access to the largest range and delivery routes of safe, reliable and high-quality CBPM, while ensuring medical practitioners have everything they need to fully support cannabis patients wherever they may be. | $13.1M / Series A / Apr 04, 2022 | |
Halo
|
Halo is a vertically integrated cannabis company that cultivates, extracts, manufactures, and distributes quality cannabis flowers, oils, and concentrates and has sold approximately nine million grams of oils and concentrates since inception. Halo continues to evolve it's business and scale efficiently, partnering with trustworthy leaders inthe industry, who value the Company’s operational expertise in bringing top-tier products to market. Current growth includes expansion in key U.S. markets, the United Kingdom and Africa, with planned expansion into the Canadian retail market. | $14M / Post-IPO Debt / Jan 06, 2022 | |
Neovacs
|
Neovacs, a spin-off from the Pierre & Marie Curie University in Paris, was founded on 1993 by Professor Daniel Zagury, one of France's most eminent immunologists and AIDS experts. Neovacs holds a broad patent portfolio and is developing several therapeutic vaccines for the treatment of AIDS, cancer and auto-immune & allergic diseases.Neovacs is acknowledged as a pioneer in the development of novel therapeutic vaccines against human cytokines (kinoids) and immunosuppressive viral proteins (toxoids). At present, monoclonal antibodies arewidely used to neutralize cytokines and treat patients suffering from cytokine-related diseases. In contrast to exogenous therapies with monoclonal antibodies, Neovacs' therapeutic vaccines induce a powerful, natural polyclonal antibody response in the patient. | $1.2M / Post-IPO Debt / Feb 08, 2021 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Alpha Blue Ocean invest in?
Alpha Blue Ocean invests primarily in Cannabis, Health Care and Biotechnology startups, most often at Post-IPO Debt and Series A stage. Most of the 8 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Alpha Blue Ocean's check size?
Alpha Blue Ocean typically joins rounds of $929k–$14M at Post-IPO Debt. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Alpha Blue Ocean participates in.
How do I contact Alpha Blue Ocean?
Public channels for Alpha Blue Ocean include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Alpha Blue Ocean?
The team at Alpha Blue Ocean includes Amaury Mamou-Mani (Co-founder and Executive Director), Amine Nedjai (CEO) and Hugo Pingray (Founder and co CIO), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
